Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells

Biochemical and Biophysical Research Communications

Volumn 320, Issue 3, 2004, Pages 825-832

  Löfgren, Christina ^a   Hjortsberg, Linn ^a   Blennow, Malin ^a   Lotfi, Kourosh ^b   Paul, Christer ^a   Eriksson, Staffan ^c   Albertioni, Freidoun ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Karolinska University Hospital ^*  (Sweden)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

5 Nucleotidase; Anthracycline; Cladribine; Cytosine arabinoside; Deoxycytidine kinase; p Glycoprotein

Indexed keywords

5' NUCLEOTIDASE; ANTHRACYCLINE; CASPASE 3; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOSIDE DERIVATIVE; VINCA ALKALOID; VINCRISTINE; VINCRISTINE SULFATE;

APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CROSS RESISTANCE; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; HUMANS; K562 CELLS; NUCLEOSIDES; P-GLYCOPROTEIN; VINCRISTINE;

VINCA;

EID: 3042719694     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.06.016     Document Type: Article

References (34)

1. Champlin R., Gale R.P. Acute myelogenous leukemia: recent advances in therapy. Blood. 69:1987;1551-1562
2. Rodriguez V., Hart J.S., Freireich E.J., Bodey G.P., McCredie K.B., Whitecar J.P. Jr., Coltman C.A. Jr. Pomp combination chemotherapy of adult acute leukemia. Cancer. 32:1973;69-75
3. Freireich E.J., Keating M.J., Gehan E.A., McCredie K.B., Bodey G.P., Smith T. Therapy of acute myelogenous leukemia. Cancer. 42:1978;874-882
4. Hu X.F., Slater A., Kantharidis P., Rischin D., Juneja S., Rossi R., Lee G., Parkin J.D., Zalcberg J.R. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood. 93:1999;4086-4095
5. Dalton W.S. Mechanisms of drug resistance in hematologic malignancies. Semin. Hematol. 34:1997;3-8
6. Beck W.T., Cirtain M.C., Danks M.K., Felsted R.L., Safa A.R., Wolverton J.S., Suttle D.P., Trent J.M. Pharmacological, molecular, and cytogenetic analysis of atypical multidrug-resistant human leukemic cells. Cancer Res. 47:1987;5455-5460
7. Leith C.P., Kopecky K.J., Chen I.-M., Eijdems L., Willman C.L. Frequency and clinical significance of the expression of multidrug resistance proteins as MDR 1/P-glycoprotein, MRP 1, and LRP in acute myeloid leukemia. A southwest oncology group study. Blood. 94:1999;1086-1099
8. Michieli M., Damiani D., Ermacora A., Masolini P., Raspadori D., Visani G., Scheper R.J., Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br. J. Haematol. 104:1999;328-335
9. Boleti H., Coe I.R., Baldwin S.A., Young J.D., Cass C.E. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology. 36:1997;1167-1179
10. Estey E., Plunkett W., Dixon D., Keating M., McCredie K., Freireich E.J. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia. 1:1987;580-583
11. Momparler R.L., Fischer G.A. Mammalian deoxynucleotide kinase I. Deoxycytidine kinase: purification, properties and kinetic studies with cytosine arabinoside. J. Biol. Chem. 243:1968;4298
12. ′ triphosphate levels in leukemic cells during treatment with high-dose 1-beta-arabinofuranosylcytosine Cancer Res. 45:1985;5952-5957
13. Kees U.R., Ford J., Dawson V.M., Piall E., Aherne G.W. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines. Cancer Res. 49:1989;3015-3019
14. Veuger M.J., Honders M.W., Landegent J.E., Willemze R., Barge R.M. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood. 96:2000;1517-1524
15. Owens J.K., Shewach D.S., Ullman B., Mitchell B.S. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. 52:1992;2389-2393
16. Nyce J., Liu L., Jones P.A. Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells. Nucleic Acids Res. 14:1986;4353-4367
17. Spasokoukotskaja T., Sasvari-Szekely M., Keszler G., Albertioni F., Eriksson S., Staub M. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur. J. Cancer. 35:1999;1862-1867
18. Laliberte J., Momparler R.L. Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res. 54:1994;5401-5407
19. ′ -nucleotidase effects of overexpression of the cloned cDNA in cultured human cells Eur. J. Biochem. 261:1999;689-697
20. Hait W.N., Choudhury S., Srimatkandada S., Murren J.R. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. J. Clin. Invest. 91:1993;2207-2215
21. Spasokoukotskaja T., Arner E.S., Brosjo O., Gunven P., Juliusson G., Liliemark J., Eriksson S. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur. J. Cancer A. 31:1995;202-208
22. ′ -nucleotidase gene expression in leukemic cells Adv. Exp. Med. Biol. 370:1994;683-687
23. Albertioni F., Gruber A., Arestrom I., Vitols S. Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia. Med. Oncol. 12:1995;79-86
24. ′ -nucleotidase mRNA measurement in cell lines and in patients with leukemia Leukemia. 16:2002;386-392
25. Grant S., Turner A., Nelms P., Yanovich S. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine. Leukemia. 9:1995;808-814
26. Mansson E., Paul A., Lofgren C., Ullberg K., Paul C., Eriksson S., Albertioni F. Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy. Br. J. Haematol. 114:2001;557-565
27. Lotfi K., Mansson E., Peterson C., Eriksson S., Albertioni F. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity. Biochem. Biophys. Res. Commun. 293:2002;1489-1496
28. Fukuda T., Kamishima T., Kakihara T., Ohnishi Y., Suzuki T. Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines. Leuk. Res. 20:1996;931-939
29. Bhalla K., Nayak R., Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine. Cancer Res. 44:1984;5029-5037
30. Lotfi K., Mansson E., Chandra J., Wang Y., Xu D., Knaust E., Spasokoukotskaja T., Liliemark E., Eriksson S., Albertioni F. Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. Br. J. Haematol. 113:2001;339-346
31. ′ -nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine Blood. 81:1993;597-601
32. Galmarini C.M., Thomas X., Graham K., El Jafaari A., Cros E., Jordheim L., Mackey J.R., Dumontet C. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br. J. Haematol. 122:2003;53-60
33. Galmarini C.M., Cros E., Graham K., Thomas X., Mackey J.R., Dumontet C. 5-(3)-Nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine. Haematologica. 89:2004;617-619
34. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., et al. Nature. 376:1995;37-43